KAZIA THERAPEUTICS LTD
Oncology-focused biotech developing targeted therapies for cancers with high unmet needs.
KZIA | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- THREE INTERNATIONAL TOWERS LEVEL 24,, 2000 SYDNEY NSW
Description
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all KAZIA THERAPEUTICS LTD filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for KAZIA THERAPEUTICS LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for KAZIA THERAPEUTICS LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
